Clinical oral investigations · 2025
Evaluating the impact of various predictors on rapid maxillary expansion (RME) success.
СтатьяКлиническое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aleesh Mahmoud Mousa, Rajeh Nada A, Aleesh Ahmad Mousa
Аннотация
OBJECTIVES: To evaluate indicators that predict the success of rapid maxillary expansion (RME) in late adolescents using pretreatment cone-beam computed tomography (CBCT).
MATERIALS AND METHODS: A prospective clinical trial was conducted to integrate radiological and clinical evaluations with blinded outcome assessment. A total of 46 patients (18 males and 28 females) with a mean age of 15.7 ± 1.4 years were enrolled. All patients were diagnosed with posterior skeletal crossbite and underwent CBCT scans prior to rapid maxillary expansion (RME) using a bonded hyrax expander. Patients were divided into Successful (S-RME) or Failed (F-RME) groups based on midpalatal suture response four days after expansion initiation. Expansion was performed twice daily and continued until molar overcorrection, followed by a four-month fixation. Four CBCT variables (midpalatal suture maturation [MSM], Cervical vertebral maturation [CVM], midpalatal suture density [MSD], and the length and thickness of the palate), age, and sex were analyzed using t-tests, Mann-Whitney U, and chi-square. ICC evaluated random errors.
RESULTS: Age, maturation stage (MSM), CVM stage, MSD, and the length of the palate were all variables with a statistically significant correlation (P <.05). Sex, as well as the thickness and area of the palate, did not show significant differences between the groups (P >. 05).
CONCLUSIONS: Patients with a higher stage of MSM and CVM had a greater risk of RME failure. Additionally, patients with a lower density ratio and shorter palate length had a better prognosis for conventional RME.
CLINICAL RELEVANCE: Choosing between traditional and surgically assisted rapid maxillary expansion (RME) is challenging, especially in late adolescents. Orthodontists should consider additional indicators to guide clinical decisions.
CLINICAL TRIAL REGISTRATION NUMBER: ISRCTN31077190.
MATERIALS AND METHODS: A prospective clinical trial was conducted to integrate radiological and clinical evaluations with blinded outcome assessment. A total of 46 patients (18 males and 28 females) with a mean age of 15.7 ± 1.4 years were enrolled. All patients were diagnosed with posterior skeletal crossbite and underwent CBCT scans prior to rapid maxillary expansion (RME) using a bonded hyrax expander. Patients were divided into Successful (S-RME) or Failed (F-RME) groups based on midpalatal suture response four days after expansion initiation. Expansion was performed twice daily and continued until molar overcorrection, followed by a four-month fixation. Four CBCT variables (midpalatal suture maturation [MSM], Cervical vertebral maturation [CVM], midpalatal suture density [MSD], and the length and thickness of the palate), age, and sex were analyzed using t-tests, Mann-Whitney U, and chi-square. ICC evaluated random errors.
RESULTS: Age, maturation stage (MSM), CVM stage, MSD, and the length of the palate were all variables with a statistically significant correlation (P <.05). Sex, as well as the thickness and area of the palate, did not show significant differences between the groups (P >. 05).
CONCLUSIONS: Patients with a higher stage of MSM and CVM had a greater risk of RME failure. Additionally, patients with a lower density ratio and shorter palate length had a better prognosis for conventional RME.
CLINICAL RELEVANCE: Choosing between traditional and surgically assisted rapid maxillary expansion (RME) is challenging, especially in late adolescents. Orthodontists should consider additional indicators to guide clinical decisions.
CLINICAL TRIAL REGISTRATION NUMBER: ISRCTN31077190.